Common adverse effects include: * oropharyngeal pain Less common adverse effects include: * musculoskeletal pain * neck pain * muscle spasms * extremity pain * muscle fatigue * anaphylaxis * malignancy The most common adverse effect of<unk>  was oropharyngeal (mouth and throat) pain. According to the phase III clinical trials data, oropharyngeal pain occurred in ≥2% of individuals along with elevated baseline creatine phosphokinase (CPK), which was more common in patients treated with<unk>  versus placebo. Myalgia was also reported more in patients in the<unk>  3 mg/kg group versus the placebo group as well as some musculoskeletal adverse reactions. Lastly, some serious adverse reactions that occurred in subjects treated with<unk>  but not in those treated with placebo included anaphylaxis and malignancy.
Reslizumab
Brolucizumab
Inebilizumab
Crizanlizumab
Tocilizumab
Risankizumab
Natalizumab
Ravulizumab